Adalimumab biosimilar exhibits same efficacy and safety for rheumatoid arthritis as originator
Patients with rheumatoid arthritis who switched from adalimumab (Humira) to its biosimilar, adalimumab-adbm (Cyltezo), saw no clinically meaningful difference, according to the results of a 48-week Phase III clinical trial…
Published: 10 November 2017